Neuroblastoma

subtype

Identifier: CI-CAN-00003408
Entity page: /cancer/neuroblastoma ↗
Edges: 823

Neighbours: 6 genes10 variants23 drugs10 trials
Drawn: 49 of 49 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,147 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Neuroblastoma approved for …APPROVED_FOR5 of 3
← approved for	Cyclophosphamidesmall_molecule	supports	FDA ORIG	Neuroblastoma	1	Regulatory	openfda	graph →
← approved for	Melphalansmall_molecule	supports	mesh_therapeutic_area

Paths

Strongest chains

Gene → variant → drug chains anchored in this cancer (or a descendant), ranked by source-native evidence level then support, with the approval and trial registry hops when they exist.

ALK R1275Q Crizotinib0 active / 2 trials
Curatedlevel Csensitivity· support 3civicObservedALK altered in 14% (64 / 471 cases, largest of 3 cohorts)no approval record in this cancercontext: Neuroblastoma
ALK F1245V EntrectinibEMA EU 2020-07-310 active / 0 trials
Curatedlevel Csensitivity· support 1civicObservedALK altered in 14% (64 / 471 cases, largest of 3 cohorts)Regulatoryapproved for Lung Non-Small Cell Carcinoma (3 approval records)context: Neuroblastoma
ALK I1171T Ceritinib1 active / 2 trials
Curatedlevel Csensitivity· support 1civicObservedALK altered in 14% (64 / 471 cases, largest of 3 cohorts)no approval record in this cancercontext: Neuroblastoma
ALK Exon 4-11 Deletion Brigatinib0 active / 0 trials
Curatedlevel Dsensitivity· support 1civicObservedALK altered in 14% (64 / 471 cases, largest of 3 cohorts)no approval record in this cancercontext: Neuroblastoma
ALK F1174L Alectinib1 active / 1 trials
Curatedlevel Dsensitivity· support 1civicObservedALK altered in 14% (64 / 471 cases, largest of 3 cohorts)no approval record in this cancercontext: Neuroblastoma
ALK F1174L ALK Inhibitor TAE6840 active / 0 trials
Curatedlevel Dsensitivity· support 1civicObservedALK altered in 14% (64 / 471 cases, largest of 3 cohorts)no approval record in this cancercontext: Neuroblastoma
ALK F1174L AZD34630 active / 0 trials
Curatedlevel Dsensitivity· support 1civicObservedALK altered in 14% (64 / 471 cases, largest of 3 cohorts)no approval record in this cancercontext: Neuroblastoma
ALK F1174L Crizotinib0 active / 2 trials
Curatedlevel Dsensitivity· support 1civicObservedALK altered in 14% (64 / 471 cases, largest of 3 cohorts)no approval record in this cancercontext: Neuroblastoma

Each hop keeps its own claim category: cohort alteration frequency (observed, cases ≥ 20), CIViC predictive edge (curated, level as stated by CIViC), regulatory approval (authority, jurisdiction, date as published), trial count (registry). A missing hop is shown as missing — never filled in. Not treatment guidance.

Neuroblastoma predicts response to …PREDICTS_RESPONSE_TO21 of 21show fewer
in context · predicts response to	ALK R1275QSNV → predicts response to Crizotinib 2 source records aggregated	sensitivity	C	Neuroblastoma	2	Curated	civic	graph →
in context · predicts response to	ALK F1245VSNV → predicts response to Entrectinib	sensitivity	C	Neuroblastoma	1	Curated	civic	graph →
in context · predicts response to	ALK F1245CSNV → predicts response to Crizotinib	resistance	C	Neuroblastoma	1	Curated	civic	graph →
in context · predicts response to	ALK I1171TSNV → predicts response to Ceritinib	sensitivity	C	Neuroblastoma	1	Curated	civic	graph →
in context · predicts response to	ALK R1275QSNV → predicts response to ALK Inhibitor TAE684	sensitivity	D	Neuroblastoma	1	Curated	civic	graph →
in context · predicts response to	MYCN Amplificationamplification → predicts response to Panobinostat	sensitivity	D	Neuroblastoma	1	Curated	civic	graph →
in context · predicts response to	MYCN Amplificationamplification → predicts response to JQ1	sensitivity	D	Neuroblastoma	1	Curated	civic	graph →
in context · predicts response to	ALK Exon 4-11 Deletiondeletion → predicts response to Brigatinib	sensitivity	D	Neuroblastoma	1	Curated	civic	graph →
in context · predicts response to	ALK F1245CSNV → predicts response to Lorlatinib	sensitivity	D	Neuroblastoma	1	Curated	civic	graph →
in context · predicts response to	ALK F1174LSNV → predicts response to AZD3463	sensitivity	D	Neuroblastoma	1	Curated	civic	graph →
in context · predicts response to	NRAS Q61KSNV → predicts response to Binimetinib	sensitivity	D	Neuroblastoma	1	Curated	civic	graph →
in context · predicts response to	NRAS Q61KSNV → predicts response to Everolimus	sensitivity	D	Neuroblastoma	1	Curated	civic	graph →
in context · predicts response to	MYCN Amplificationamplification → predicts response to FACT Complex-targeting Curaxin CBL0137	sensitivity	D	Neuroblastoma	1	Curated	civic	graph →
in context · predicts response to	ALK R1275QSNV → predicts response to Crizotinib	sensitivity	D	Neuroblastoma	1	Curated	civic	graph →
in context · predicts response to	ALK F1174LSNV → predicts response to Crizotinib	resistance	D	Neuroblastoma	1	Curated	civic	graph →
in context · predicts response to	ALK R1275QSNV → predicts response to ALK Inhibitor TAE684	resistance	D	Neuroblastoma	1	Curated	civic	graph →
in context · predicts response to	ALK F1174LSNV → predicts response to Crizotinib	sensitivity	D	Neuroblastoma	1	Curated	civic	graph →
in context · predicts response to	ALK F1174LSNV → predicts response to Alectinib	sensitivity	D	Neuroblastoma	1	Curated	civic	graph →
in context · predicts response to	ALK R1275QSNV → predicts response to Lorlatinib	sensitivity	D	Neuroblastoma	1	Curated	civic	graph →
in context · predicts response to	ALK F1174LSNV → predicts response to Lorlatinib	sensitivity	D	Neuroblastoma	1	Curated	civic	graph →
in context · predicts response to	ALK F1174LSNV → predicts response to ALK Inhibitor TAE684	sensitivity	D	Neuroblastoma	1	Curated	civic	graph →

Neuroblastoma prognostic in …PROGNOSTIC_IN3 of 3
← prognostic in	MYCN Amplificationamplification	supports	A	Neuroblastoma	1	Curated	civic	graph →
← prognostic in	CASP8 D302HSNV	supports	B	Neuroblastoma	1	Curated	civic	graph →
← prognostic in	NTRK1 Overexpressionexpression	supports	B	Neuroblastoma	1	Curated	civic	graph →

Neuroblastoma associated with …ASSOCIATED_WITH7 of 7
← associated with	MYCN	supports	A	Neuroblastoma	1	Curated	civic	graph →
← associated with	CASP8	supports	B	Neuroblastoma	1	Curated	civic	graph →
← associated with	NTRK1	supports	B	Neuroblastoma	1	Curated	civic	graph →
← associated with	ALK 5 source records aggregated	supports	C	Neuroblastoma	5	Curated	civic	graph →
← associated with	ALK 12 source records aggregated	supports	D	Neuroblastoma	12	Curated	civic	graph →
← associated with	MYCN 2 source records aggregated	supports	D	Neuroblastoma	2	Curated	civic	graph →
← associated with	NRAS	supports	D	Neuroblastoma	1	Curated	civic	graph →

Neuroblastoma investigated for …INVESTIGATED_FOR15 of 72show all (up to 200)
← investigated for	Melphalansmall_molecule	unknown	4	Neuroblastoma	1	Curated	chembl	graph →
← investigated for	Dinutuximab Betamonoclonal_antibody	unknown	4	Neuroblastoma	1	Curated	chembl	graph →
← investigated for	Dinutuximabmonoclonal_antibody	unknown	4	Neuroblastoma	1	Curated	chembl	graph →
← investigated for	Crizotinibsmall_molecule 3 source records aggregated	supports	C	Neuroblastoma	3	Curated	civic	graph →
← investigated for	Entrectinibsmall_molecule	supports	C	Neuroblastoma	1	Curated	civic	graph →
← investigated for	Ceritinibsmall_molecule	supports	C	Neuroblastoma	1	Curated	civic	graph →
← investigated for	Vindesinesmall_molecule	unknown	3	Neuroblastoma	1	Curated	chembl	graph →
← investigated for	Vincristinesmall_molecule	unknown	3	Neuroblastoma	1	Curated	chembl	graph →
← investigated for	Topotecansmall_molecule	unknown	3	Neuroblastoma	1	Curated	chembl	graph →
← investigated for	Thiotepasmall_molecule	unknown	3	Neuroblastoma	1	Curated	chembl	graph →
← investigated for	Temozolomidesmall_molecule	unknown	3	Neuroblastoma	1	Curated	chembl	graph →
← investigated for	Prednisonesmall_molecule	unknown	3	Neuroblastoma	1	Curated	chembl	graph →
← investigated for	Lorlatinibsmall_molecule	unknown	3	Neuroblastoma	1	Curated	chembl	graph →
← investigated for	Irinotecansmall_molecule	unknown	3	Neuroblastoma	1	Curated	chembl	graph →
← investigated for	Ifosfamidesmall_molecule	unknown	3	Neuroblastoma	1	Curated	chembl	graph →

Neuroblastoma altered in cohorts of …ALTERED_INderived2 of 2
← altered in cohorts of	ALK 64 / 471 cases (14 %) · ssm · nbl_target_gdc · largest of 3 cohorts	—	—	Neuroblastoma	3	Observed	cbioportal	graph →
← altered in cohorts of	ATRX 24 / 223 cases (11 %) · ssm · nbl_msk_2023	—	—	Neuroblastoma	1	Observed	cbioportal	graph →

Neuroblastoma investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 99show all (up to 200)
→ investigated in trials for	Cyclophosphamidesmall_molecule 89 trials (21 active) · roll-up of the cancer and its descendants	—	—	Neuroblastoma	89	Observed	clinicaltrials	graph →
→ investigated in trials for	Etoposidesmall molecule 58 trials (8 active) · roll-up of the cancer and its descendants	—	—	Neuroblastoma	58	Observed	clinicaltrials	graph →
→ investigated in trials for	Carboplatinsmall molecule 51 trials (8 active) · roll-up of the cancer and its descendants	—	—	Neuroblastoma	51	Observed	clinicaltrials	graph →
→ investigated in trials for	Vincristinesmall_molecule 47 trials (8 active) · roll-up of the cancer and its descendants	—	—	Neuroblastoma	47	Observed	clinicaltrials	graph →
→ investigated in trials for	Filgrastimother 42 trials (1 active) · roll-up of the cancer and its descendants	—	—	Neuroblastoma	42	Observed	clinicaltrials	graph →
→ investigated in trials for	Doxorubicinsmall molecule 40 trials (6 active) · roll-up of the cancer and its descendants	—	—	Neuroblastoma	40	Observed	clinicaltrials	graph →
→ investigated in trials for	Melphalansmall_molecule 40 trials (5 active) · roll-up of the cancer and its descendants	—	—	Neuroblastoma	40	Observed	clinicaltrials	graph →
→ investigated in trials for	Topotecansmall_molecule 37 trials (10 active) · roll-up of the cancer and its descendants	—	—	Neuroblastoma	37	Observed	clinicaltrials	graph →
→ investigated in trials for	Temozolomidesmall_molecule 35 trials (17 active) · roll-up of the cancer and its descendants	—	—	Neuroblastoma	35	Observed	clinicaltrials	graph →
→ investigated in trials for	Cisplatinsmall molecule 31 trials (4 active) · roll-up of the cancer and its descendants	—	—	Neuroblastoma	31	Observed	clinicaltrials	graph →
→ investigated in trials for	Irinotecansmall_molecule 31 trials (14 active) · roll-up of the cancer and its descendants	—	—	Neuroblastoma	31	Observed	clinicaltrials	graph →
→ investigated in trials for	Busulfansmall molecule 20 trials (3 active) · roll-up of the cancer and its descendants	—	—	Neuroblastoma	20	Observed	clinicaltrials	graph →
→ investigated in trials for	Fludarabinesmall molecule 19 trials (7 active) · roll-up of the cancer and its descendants	—	—	Neuroblastoma	19	Observed	clinicaltrials	graph →
→ investigated in trials for	Thiotepasmall_molecule 19 trials (5 active) · roll-up of the cancer and its descendants	—	—	Neuroblastoma	19	Observed	clinicaltrials	graph →
→ investigated in trials for	Dinutuximabmonoclonal_antibody 17 trials (10 active) · roll-up of the cancer and its descendants	—	—	Neuroblastoma	17	Observed	clinicaltrials	graph →

Neuroblastoma studied in …STUDIED_INderived10 of 616show all (up to 200)
→ studied in	NCT04724369Phase 3 · completed Open-Label Study of 18F-mFBG for Imaging Neuroblastoma · condition mapped ONTOLOGY_EXACT · 616 trials mapped (164 active)	—	—	Neuroblastoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06479811Phase 1 · recruiting [212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers · condition mapped ALIAS · 616 trials mapped (164 active)	—	—	Olfactory Neuroblastoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT01109394recruiting Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological Studies · condition mapped ONTOLOGY_EXACT · 616 trials mapped (164 active)	—	—	Neuroblastoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06172296Phase 3 · recruiting Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma · condition mapped ONTOLOGY_EXACT · 616 trials mapped (164 active)	—	—	Neuroblastoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06995872Phase 1 · recruiting Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory Neuroblastoma · condition mapped ONTOLOGY_EXACT · 616 trials mapped (164 active)	—	—	Neuroblastoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04837547Phase 1 · active not recruiting PEACH TRIAL- Precision Medicine and Adoptive Cellular Therapy · condition mapped ONTOLOGY_EXACT · 616 trials mapped (164 active)	—	—	Neuroblastoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT01005654recruiting Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms · condition mapped ONTOLOGY_EXACT · 616 trials mapped (164 active)	—	—	Neuroblastoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT01857934Phase 2 · completed Therapy for Children With Advanced Stage Neuroblastoma · condition mapped ONTOLOGY_EXACT · 616 trials mapped (164 active)	—	—	Neuroblastoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03210714Phase 2 · active not recruiting Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) · condition mapped CURATED_BROADER · 616 trials mapped (164 active)	—	—	Neuroblastoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06814496Phase 1/Phase 2 · recruiting Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors · condition mapped ALIAS · 616 trials mapped (164 active)	—	—	Olfactory Neuroblastoma	1	Observed	clinicaltrials	graph →